The issue with CU64 is not what it’s capable of, it’s the commercial viability due to supply chain issues and significant clinical deployment issues.
Even if clinicians wanted CU 100% of the time you have to get it to them in a cost effective, safe, consistent easy to use way. The benefit and altered patient treatment would have to be substantial vs GA however I don’t believe that to be the case, at least there is no current evidence. LU can pick up small legions to.
Agreed it’s not either or however I can’t see CU taking off given the reasons above.
Cheers
- Forums
- ASX - By Stock
- TLX
- Understanding Telix
Understanding Telix, page-1404
Featured News
Add TLX (ASX) to my watchlist
|
|||||
Last
$18.61 |
Change
0.130(0.70%) |
Mkt cap ! $6.227B |
Open | High | Low | Value | Volume |
$18.69 | $18.80 | $18.37 | $19.72M | 1.061M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 161 | $18.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.62 | 450 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 26 | 18.450 |
1 | 108 | 18.430 |
1 | 163 | 18.350 |
1 | 5000 | 18.310 |
3 | 6163 | 18.300 |
Price($) | Vol. | No. |
---|---|---|
18.620 | 450 | 1 |
18.700 | 400 | 1 |
18.900 | 1500 | 1 |
19.010 | 3200 | 2 |
19.050 | 512 | 1 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online